Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Ibuprofen
Sponsored by

About this trial
This is an interventional basic science trial for Obesity focused on measuring Iron bioavailability, Inflammation, Hepcidin, Iron absorption
Eligibility Criteria
Inclusion Criteria:
- normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2)
- pre-menopausal
- no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity
- no-smoking
Exclusion Criteria:
- Diagnosed chronic disease or gastrointestinal disorders
- Metabolic disorders (e.g. diabetes)
- Regular use of medication (except oral contraceptives)
- Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study
- Pregnancy or lactation
Sites / Locations
- Human Nutrition Laboratory ETH Zurich
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
normal-weight
obesity
Arm Description
normal-weight women
obese women
Outcomes
Primary Outcome Measures
Fractional iron absorption
The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals. Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic. The investigators assumed iron incorporation into erythrocytes to be constant. Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.
Secondary Outcome Measures
Plasma ferritin
Hemoglobin
Transferrin receptor
Hepcidin
c-reactive protein
interleukin-6
alpha-1-acid-glycoprotein
Full Information
NCT ID
NCT02745925
First Posted
April 18, 2016
Last Updated
October 3, 2019
Sponsor
Swiss Federal Institute of Technology
Collaborators
University of Monterrey, Mexico
1. Study Identification
Unique Protocol Identification Number
NCT02745925
Brief Title
Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation
Official Title
Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
December 2018 (Actual)
Study Completion Date
December 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Swiss Federal Institute of Technology
Collaborators
University of Monterrey, Mexico
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main iron regulatory protein in the human metabolism is hepcidin. In normal weight, healthy subjects, hepcidin is regulated through the iron status of the body: low iron status results in low hepcidin concentrations, which facilitates dietary iron absorption. In obesity, which is an inflammatory state, hepcidin concentrations are increased and iron absorption is reduced despite low iron stores, leading to iron deficiency over time. Whether lowering the chronic low-grade inflammation during a limited treatment period and thereby lowering hepcidin concentration can improve iron absorption is uncertain.
Detailed Description
In states of high hepcidin concentration, intestinal iron absorption (through enterocytes) and recycling of iron (through macrophages) is reduced. The extent to which non-heme iron is absorbed from the diet is influenced by the composition of the diet. Ascorbic acid is a potent enhancer of non-heme iron absorption. It's mechanism of action is luminal reduction of dietary ferric iron (Fe3+) to more soluble ferrous iron (Fe2+). A study in the inestigator's laboratory showed that the enhancing effect of ascorbic acid on non-heme iron absorption is reduced in overweight and obese individuals. Possible explanations for this fact are the different sites of action of ascorbic acid and serum hepcidin on the enterocytes in dietary iron absorption. Increased hepcidin reduces iron efflux into the circulation at the basolateral membrane of the enterocyte. Therefore the improved iron transport into enterocytes through ascorbic acid at the luminal side (via the divalent metal transporter (DMT)-1), by reducing Fe3+ to Fe2+ seems to be less successful. To improve iron absorption in obese subjects, an intervention at the basolateral membrane of the enterocyte would be needed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Iron bioavailability, Inflammation, Hepcidin, Iron absorption
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
normal-weight
Arm Type
Experimental
Arm Description
normal-weight women
Arm Title
obesity
Arm Type
Experimental
Arm Description
obese women
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Primary Outcome Measure Information:
Title
Fractional iron absorption
Description
The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals. Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic. The investigators assumed iron incorporation into erythrocytes to be constant. Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.
Time Frame
Days 15 and 45
Secondary Outcome Measure Information:
Title
Plasma ferritin
Time Frame
Days 1, 15, 30, 45
Title
Hemoglobin
Time Frame
Days 1, 15, 30, 45
Title
Transferrin receptor
Time Frame
Days 1, 15, 30, 45
Title
Hepcidin
Time Frame
Days 1, 15, 30, 45
Title
c-reactive protein
Time Frame
Days 1, 15, 30, 45
Title
interleukin-6
Time Frame
Days 1, 15, 30, 45
Title
alpha-1-acid-glycoprotein
Time Frame
Days 1, 15, 30, 45
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2)
pre-menopausal
no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity
no-smoking
Exclusion Criteria:
Diagnosed chronic disease or gastrointestinal disorders
Metabolic disorders (e.g. diabetes)
Regular use of medication (except oral contraceptives)
Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study
Pregnancy or lactation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Isabelle Herter-Aeberli, PhD
Organizational Affiliation
University of Zurich
Official's Role
Principal Investigator
Facility Information:
Facility Name
Human Nutrition Laboratory ETH Zurich
City
Zurich
ZIP/Postal Code
8092
Country
Switzerland
12. IPD Sharing Statement
Learn more about this trial
Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation
We'll reach out to this number within 24 hrs